CoChat

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Cortellini, Alessio, Bersanelli, Melissa, Santini, Daniele, Buti, Sebastiano, Tiseo, Marcello, Cannita, Katia, Perrone, Fabiana, Giusti, Raffaele, De Tursi, Michele, Zoratto, Federica, Marconcini, Riccardo, Russano, Marco, Zeppola, Tea, Anesi, Cecilia, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Tudini, Marianna, Silva, Rosa Rita, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Migliorino, Maria Rita, Mallardo, Domenico, Vanella, Vito, Mosillo, Claudia, Bracarda, Sergio, Rinaldi, Silvia, Berardi, Rossana, Natoli, Clara, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A. · 2020 · European Journal of Cancer
Cited by 127

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND Several studies have found an association between higher body mass index (BMI) and improved clinical outcomes in cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors. In a previous study, we found that overweight/obese patients were significantly more likely to experience any grade immune-related adverse events (irAEs) compared to non-overweight patients. PATIENTS AND METHODS We conducted a 'real-life', multi centre, retrospective observational study aimed at comparing the incidence of irAEs among cancer patients treated with PD-1/PD-L1 inhibitors according to baseline BMI. RESULTS One thousand and seventy advanced cancer patients were evaluated. The median age was 68 years (range: 21-92), male/female ratio was 724/346. Primary tumours were: non-small-cell lung carcinoma (NSCLC) (653 patients), melanoma (233 patients), renal cell carcinoma (RCC) (152 patients) and others (29 patients). Median BMI was 25 (13.6-46.6); according to World Health Organisation (WHO) classification, 44 patients (4.1%) were defined as underweight, 480 patients (44.9%) as having a normal weight, 416 patients (38.9%) as overweight and 130 patients (12.1%) as obese. Higher BMI was significantly related to higher occurrence of any grade immune-related adverse events [irAEs] (p < 0.0001), G3/G4 irAEs (p < 0.0001) and irAEs leading to discontinuation (LTD) (p < 0.0001). Overweight and obesity were confirmed predictors for irAEs of any grade at both univariate and multivariate analysis. The adjusted odds ratios (ORs) (compared to normal-weight) were 10.6; 95% confidence interval (95%CI): 7.5-14.9 for overweight, and 16.6 (95%CI: 10.3-26.7) for obese patients. Obesity was the only factor significantly related to a higher incidence of G3/G4 irAEs (OR = 11.9 [95%CI: 6.4-22.3], p < 0.0001) and LTD irAEs (OR = 8.8 [95%CI: 4.3-18.2], p < 0.0001). Overweight and obese patients experienced a significantly higher occurrence of cutaneous, endocrine, gastro-intestinal (GI), hepatic and 'others' irAEs, compared to normal-weight patients. Only obese patients experienced a significantly higher occurrence of pulmonary and rheumatic irAEs, compared to normal-weight patients. CONCLUSIONS Considering the previously evidenced association between higher BMI and better outcome, the current finding about the relationship between BMI and irAEs occurrence can contribute to consideration of these findings as the upside of the downside, which underlies an 'immunogenic phenotype'.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2019.12.031

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 127

Metadata

Authors
Cortellini, A., Bersanelli, M., Santini, D., Buti, S., Tiseo, M., Cannita, K., Perrone, F., Giusti, R., De Tursi, M., Zoratto, F., Marconcini, R., Russano, M., Zeppola, T., Anesi, C., Filetti, M., Marchetti, P., Botticelli, A., Gelibter, A., De Galitiis, F., Vitale, M. G., Rastelli, F., Tudini, M., Silva, R. R., Atzori, F., Chiari, R., Ricciuti, B., De Giglio, A., Migliorino, M. R., Mallardo, D., Vanella, V., Mosillo, C., Bracarda, S., Rinaldi, S., Berardi, R., Natoli, C., Ficorella, C., Porzio, G., & Ascierto, P. A.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2020-03
Volume
128
Pages
17-26
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3012135573
Cited by
127
References
12
FWCI
6.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.